Doriano Lamba – Dr. Doriano Lamba, obtained a degree in Chemistry (1980) University of Rome “La Sapienza” and a PhD in Biophysics (1988) Astubury Dept of Biophysics, Leeds University (UK). Post Doc in Protein Crystallography (1993-1996) at MPI – Biochemistry,Muenchen (DE).
Deputy Head of the Trieste Outstation of IC-CNR (2010-2018). Guest Scientist at ICGEB and associated Senior Scientist at ISAS, Trieste (1997-2005).
Adjunct professor (2010-2017) in Structural Biology at SNS, Pisa. Adjunct professor (2017-) in Synchrotron Radiation Applications in Structural Biology – Università degli Studi di Trieste.
Italian delegate INPEC (2009-). Member (2013-) of the steering committee CRG-IN13 CNR-ILL, Grenoble (FR), and president (2012-) of the scientific panel review committee CRG GILDA –CNR, ESRF, Grenoble(FR).
Member of the Italian delegation -European Synchrotron User Organization (2016-).
Dr. Lamba’s research fields are biochemistry, biophysics, biocrystallography and structure-based drug design.
His career has been constantly centered on the structure-activity-function relationships of key biomedical protein targets implicated in several physiological and pathological states (coagulation, fibrinolysis, Alzheimer’s disease, neuropathic chronic pain).
He is partner of several projects funded by the Italian Ministry of Research and EU, and actively collaborates with a number of pharmaceutical companies. He has authored 113 publications on international ISI journals with an H index of 26 (ISI WOS).
Selected Publications(2014-2018)
1.Nepovimova E., Uliassi E., Korabecny J., Peña-Altamira L. , Samez S., Pesaresi A., Garcia G.E., Bartolini M., Andrisano V.,Bergamini C., Fato R., Lamba D., Roberti M., Kuca K., Monti B., Bolognesi M.L. “Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects” J. Med. Chem. 57, 8576–8589 (2014)
2.Paoletti F., Malerba F., Bruni E. P., Lamba D., Cattaneo A. “A comparative analysis of the structural, functional and biological differences between mouse and human nerve growth factor” Biochimica et Biophysica Acta – Proteins and Proteomics 1854, 187-197 (2015)
3.Covaceuszach S., Konarev P. V., Cassetta, A., Paoletti F., Svergun D.I., Lamba D., Cattaneo A. “The conundrum of the “high affinity” NGF binding sites formation unveiled?” Biophysical J. 108, 687-697 (2015)
4.Bozzi M., Cassetta A., Covaceuszach S., Bigotti M.G., Bannister S., Hübner W., Sciandra F., Lamba D., Brancaccio A. “The Structure of the T190M Mutant of Murine a-Dystroglycan at High Resolution: Insight into the Molecular Basis of a Primary Dystroglycanopathy. PLos ONE 10, e0124277 (2015)
5.Malerba, F.; Paoletti, F.; Bruni E.B.; Materazzi, S.; Nassini, R.; Coppi, E.; Patacchini, R.; Capsoni, S.; Lamba, D.; Cattaneo, A. “Functional characterization of human proNGF and NGF mutants: identification of NGF P61SR100E as a ‘painless’ lead investigational candidate for therapeutic applications” PLos ONE 10, e0136425 (2015)
6.Zha X., Lamba D., Zhang L., Lou Y., Zhou C., Xua C., Kang D., Chen L., Xu Y., Zhang L., De Simone A., Samez S., Pesaresi A., Stojan J., Garcia M., Egea J., Andrisano V., Bartolini M. “Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease:Design, Synthesis, Biological Evaluation and X-ray Crystallography” J. Med. Chem. 59, 114-131 (2016)
7.Paoletti F., De Chiara C., Kelly G., Covaceuszach S., Malerba F., Yan R., Lamba D., Cattaneo A., Pastore A. “Conformational rigidity within plasticity promotes differential target recognition of Nerve Growth Factor”. Frontiers in Molecular Biosciences 3,83 (2016)
8.Cassetta A., Stojan J., Krastanova I., Kristan K., Brunskole Švegelj M., Lamba D., Lanišnik Rižner T. “Structural basis for inhibition of 17β-hydroxysteroid dehydrogenases by phytoestrogens: the case of fungal 17β-HSDcl” The Journal of Steroid Biochemistry and Molecular Biology 171, 80-93 (2017)
Patent
Cattaneo A., Covaceuszach S., Lamba D. Method for the humanization of antibodies and humanized antibodies thereby obtained”. Patent WO/2005/061540. Licensed to: Bioxell SpA (2005); Pangenetics B.V.(2006); Abbott (2009); Glenmark Pharma (2010).
Deputy Head of the Trieste Outstation of IC-CNR (2010-2018). Guest Scientist at ICGEB and associated Senior Scientist at ISAS, Trieste (1997-2005).
Adjunct professor (2010-2017) in Structural Biology at SNS, Pisa. Adjunct professor (2017-) in Synchrotron Radiation Applications in Structural Biology – Università degli Studi di Trieste.
Italian delegate INPEC (2009-). Member (2013-) of the steering committee CRG-IN13 CNR-ILL, Grenoble (FR), and president (2012-) of the scientific panel review committee CRG GILDA –CNR, ESRF, Grenoble(FR).
Member of the Italian delegation -European Synchrotron User Organization (2016-).
Dr. Lamba’s research fields are biochemistry, biophysics, biocrystallography and structure-based drug design.
His career has been constantly centered on the structure-activity-function relationships of key biomedical protein targets implicated in several physiological and pathological states (coagulation, fibrinolysis, Alzheimer’s disease, neuropathic chronic pain).
He is partner of several projects funded by the Italian Ministry of Research and EU, and actively collaborates with a number of pharmaceutical companies. He has authored 113 publications on international ISI journals with an H index of 26 (ISI WOS).
Selected Publications(2014-2018)
1.Nepovimova E., Uliassi E., Korabecny J., Peña-Altamira L. , Samez S., Pesaresi A., Garcia G.E., Bartolini M., Andrisano V.,Bergamini C., Fato R., Lamba D., Roberti M., Kuca K., Monti B., Bolognesi M.L. “Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects” J. Med. Chem. 57, 8576–8589 (2014)
2.Paoletti F., Malerba F., Bruni E. P., Lamba D., Cattaneo A. “A comparative analysis of the structural, functional and biological differences between mouse and human nerve growth factor” Biochimica et Biophysica Acta – Proteins and Proteomics 1854, 187-197 (2015)
3.Covaceuszach S., Konarev P. V., Cassetta, A., Paoletti F., Svergun D.I., Lamba D., Cattaneo A. “The conundrum of the “high affinity” NGF binding sites formation unveiled?” Biophysical J. 108, 687-697 (2015)
4.Bozzi M., Cassetta A., Covaceuszach S., Bigotti M.G., Bannister S., Hübner W., Sciandra F., Lamba D., Brancaccio A. “The Structure of the T190M Mutant of Murine a-Dystroglycan at High Resolution: Insight into the Molecular Basis of a Primary Dystroglycanopathy. PLos ONE 10, e0124277 (2015)
5.Malerba, F.; Paoletti, F.; Bruni E.B.; Materazzi, S.; Nassini, R.; Coppi, E.; Patacchini, R.; Capsoni, S.; Lamba, D.; Cattaneo, A. “Functional characterization of human proNGF and NGF mutants: identification of NGF P61SR100E as a ‘painless’ lead investigational candidate for therapeutic applications” PLos ONE 10, e0136425 (2015)
6.Zha X., Lamba D., Zhang L., Lou Y., Zhou C., Xua C., Kang D., Chen L., Xu Y., Zhang L., De Simone A., Samez S., Pesaresi A., Stojan J., Garcia M., Egea J., Andrisano V., Bartolini M. “Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease:Design, Synthesis, Biological Evaluation and X-ray Crystallography” J. Med. Chem. 59, 114-131 (2016)
7.Paoletti F., De Chiara C., Kelly G., Covaceuszach S., Malerba F., Yan R., Lamba D., Cattaneo A., Pastore A. “Conformational rigidity within plasticity promotes differential target recognition of Nerve Growth Factor”. Frontiers in Molecular Biosciences 3,83 (2016)
8.Cassetta A., Stojan J., Krastanova I., Kristan K., Brunskole Švegelj M., Lamba D., Lanišnik Rižner T. “Structural basis for inhibition of 17β-hydroxysteroid dehydrogenases by phytoestrogens: the case of fungal 17β-HSDcl” The Journal of Steroid Biochemistry and Molecular Biology 171, 80-93 (2017)
Patent
Cattaneo A., Covaceuszach S., Lamba D. Method for the humanization of antibodies and humanized antibodies thereby obtained”. Patent WO/2005/061540. Licensed to: Bioxell SpA (2005); Pangenetics B.V.(2006); Abbott (2009); Glenmark Pharma (2010).